Anti-HIV Agents

"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Descriptor ID	D019380
MeSH Number(s)	D27.505.954.122.388.077.088
Concept/Terms	Anti-HIV Agents Anti-HIV Agents Agents, Anti-HIV Anti HIV Agents Anti-AIDS Agents Agents, Anti-AIDS Anti AIDS Agents Anti-HIV Drugs Anti HIV Drugs Drugs, Anti-HIV AIDS Drugs Drugs, AIDS Anti-AIDS Drugs Anti AIDS Drugs Drugs, Anti-AIDS

Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]
Anti-Retroviral Agents [D27.505.954.122.388.077]
Anti-HIV Agents [D27.505.954.122.388.077.088]

Below are MeSH descriptors whose meaning is related to "Anti-HIV Agents".

Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.

Bar chart showing 304 publications over 28 distinct years, with a maximum of 23 publications in 2017 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	1	2
1998	1	1	2
2000	0	1	1
2001	0	3	3
2002	2	2	4
2003	5	4	9
2004	6	3	9
2005	2	6	8
2006	4	3	7
2007	8	5	13
2008	4	1	5
2009	3	1	4
2010	9	1	10
2011	7	4	11
2012	10	3	13
2013	9	6	15
2014	10	2	12
2015	13	3	16
2016	15	3	18
2017	19	4	23
2018	8	9	17
2019	11	5	16
2020	16	7	23
2021	15	5	20
2022	8	0	8
2023	6	0	6
2024	6	8	14
2025	12	3	15

Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.

Madlala HP, Jao J, Roussos G, Mendham AE, Myer L, Abrams E, Geffen H, Mukonda E, Modibedi R, Odayar J, Matyesini S, Dugas LR, Goedecke JH, Catalano P, McComsey GA, Gerschenson M. Gluteal Adipose Tissue Mitochondrial Respiration and Insulin Sensitivity in Pregnant South African Women Living With HIV on Tenofovir-Lamivudine-Dolutegravir. J Acquir Immune Defic Syndr. 2025 Dec 15; 100(5):462-470.

View in: PubMed
Ndhlovu LC, Giron LB, Galinskas J, Premeaux TA, Pang APS, Dias D, de Almeida Baptista MV, Shytaj IL, Maricato JT, Ferreira PRA, Gosuen G, Corley MJ, Friday CM, Bowler SA, Della Libera E, Sucupira MC, Hunter JR, Janini LM, Schechter M, Savarino A, Diaz RS. Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV. J Infect Dis. 2025 Nov 14; 232(5):1067-1077.

View in: PubMed
Nawfal ES, Gray A, Ladner R, Li T, Sheehan DM, Fennie K, Jean-Gilles M, Ward MK, Fernandez SB, Beach MC, D?vieux JG, Trepka MJ. Race- and ethnicity-specific patient-provider relationship characteristics associated with antiretroviral therapy adherence and viral suppression among minority women with HIV, Miami-Dade County, Florida, 2021-2022. AIDS Care. 2025 Nov; 37(11):1843-1856.

View in: PubMed
Allen DC, Rabionet SE, Dale SK, Popovici I. What Is the Effect of Medicaid Expansions on Preexposure Prophylaxis for HIV Prevention Use among Women? AIDS Behav. 2025 Dec; 29(12):3916-3930.

View in: PubMed
Allen DC, Rabionet SE, Dale SK, Zorrilla CD, Silva-Suarez G, Popovici I. Using epidemiological data to explore the impact of mental health and substance use disorder treatment facilities and family planning clinic availability on pre-exposure prophylaxis use for women in the U.S. AIDS Care. 2025 Aug; 37(8):1271-1282.

View in: PubMed
Coleman MI, Khan MB, Gbodossou E, Diop A, DeBarros K, Bond VC, Floyd V, Kondwani K, Rice VM, Powell MD. Plant Lectin, MoMo30, Pressures HIV-1 to Select for Variants with Deleted N-Linked Glycosylation Sites. Viruses. 2025 06 27; 17(7).

View in: PubMed
Sutar Y, Adams JS, Wu X, Bhoyarekar V, Garcia Diaz M, Wallace J, Dave M, Zhang QY, Date AA. Rilpivirine Ionic Liquid Nanoemulsion Augments the Oral Bioavailability of Rilpivirine and Its Delivery to the HIV Sanctuary Sites. ACS Appl Mater Interfaces. 2025 Jun 04; 17(22):31954-31970.

View in: PubMed
Sheehan DM, Ram?rez-Ortiz D, Gwanzura T, Lewis PS, Ertl MM, Duncan DT, Swendeman D, Mu?oz-Laboy M, Devieux JG, Trepka MJ. Daily Factors Associated with Antiretroviral Therapy Adherence Among Young Latino Sexual Minority Men with HIV: A 28-Day Daily Diary Study. AIDS Behav. 2025 Oct; 29(10):3054-3069.

View in: PubMed
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clin Infect Dis. 2025 Apr 30; 80(4):881-888.

View in: PubMed
Chandler CJ, Schlundt DG, Dagostino C, Bonnet KR, Sellers AJ, Pichon LC, Alexander LR. PrEP Navigator Perceptions of the Implementation of Injectable PrEP on HIV Prevention in Tennessee. Int J Environ Res Public Health. 2025 Apr 23; 22(5).

View in: PubMed

People

Explore

Similar Concepts

Top Journals